PMC:7600245 / 59620-60944 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T261","span":{"begin":174,"end":178},"obj":"Body_part"},{"id":"T262","span":{"begin":226,"end":230},"obj":"Body_part"},{"id":"T263","span":{"begin":322,"end":325},"obj":"Body_part"},{"id":"T264","span":{"begin":330,"end":337},"obj":"Body_part"},{"id":"T265","span":{"begin":648,"end":651},"obj":"Body_part"},{"id":"T266","span":{"begin":846,"end":854},"obj":"Body_part"},{"id":"T267","span":{"begin":884,"end":887},"obj":"Body_part"},{"id":"T268","span":{"begin":964,"end":968},"obj":"Body_part"}],"attributes":[{"id":"A261","pred":"fma_id","subj":"T261","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A262","pred":"fma_id","subj":"T262","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A263","pred":"fma_id","subj":"T263","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A264","pred":"fma_id","subj":"T264","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A265","pred":"fma_id","subj":"T265","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A266","pred":"fma_id","subj":"T266","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A267","pred":"fma_id","subj":"T267","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A268","pred":"fma_id","subj":"T268","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T24","span":{"begin":964,"end":968},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T263","span":{"begin":111,"end":119},"obj":"Disease"},{"id":"T264","span":{"begin":155,"end":164},"obj":"Disease"},{"id":"T265","span":{"begin":313,"end":321},"obj":"Disease"},{"id":"T266","span":{"begin":435,"end":450},"obj":"Disease"},{"id":"T267","span":{"begin":481,"end":489},"obj":"Disease"},{"id":"T268","span":{"begin":706,"end":710},"obj":"Disease"},{"id":"T269","span":{"begin":735,"end":752},"obj":"Disease"},{"id":"T270","span":{"begin":740,"end":752},"obj":"Disease"},{"id":"T271","span":{"begin":764,"end":773},"obj":"Disease"},{"id":"T272","span":{"begin":958,"end":975},"obj":"Disease"},{"id":"T274","span":{"begin":969,"end":975},"obj":"Disease"},{"id":"T275","span":{"begin":1061,"end":1069},"obj":"Disease"},{"id":"T276","span":{"begin":1106,"end":1114},"obj":"Disease"},{"id":"T277","span":{"begin":1192,"end":1200},"obj":"Disease"},{"id":"T278","span":{"begin":1221,"end":1241},"obj":"Disease"},{"id":"T279","span":{"begin":1300,"end":1308},"obj":"Disease"}],"attributes":[{"id":"A263","pred":"mondo_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A264","pred":"mondo_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A265","pred":"mondo_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A266","pred":"mondo_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/MONDO_0002269"},{"id":"A267","pred":"mondo_id","subj":"T267","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A268","pred":"mondo_id","subj":"T268","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A269","pred":"mondo_id","subj":"T269","obj":"http://purl.obolibrary.org/obo/MONDO_0017880"},{"id":"A270","pred":"mondo_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/MONDO_0005706"},{"id":"A271","pred":"mondo_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A272","pred":"mondo_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A273","pred":"mondo_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/MONDO_0015796"},{"id":"A274","pred":"mondo_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A275","pred":"mondo_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A276","pred":"mondo_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A277","pred":"mondo_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A278","pred":"mondo_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/MONDO_0004768"},{"id":"A279","pred":"mondo_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T605","span":{"begin":58,"end":59},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T606","span":{"begin":62,"end":64},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T607","span":{"begin":121,"end":126},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T608","span":{"begin":149,"end":154},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"},{"id":"T609","span":{"begin":165,"end":170},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T610","span":{"begin":174,"end":178},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T611","span":{"begin":200,"end":201},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T612","span":{"begin":226,"end":230},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T613","span":{"begin":282,"end":283},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T614","span":{"begin":368,"end":369},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T615","span":{"begin":490,"end":495},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T616","span":{"begin":549,"end":550},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T617","span":{"begin":551,"end":554},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T618","span":{"begin":711,"end":716},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T619","span":{"begin":728,"end":733},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T620","span":{"begin":753,"end":758},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T621","span":{"begin":774,"end":775},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T622","span":{"begin":776,"end":781},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T623","span":{"begin":964,"end":968},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T624","span":{"begin":964,"end":968},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T625","span":{"begin":1017,"end":1018},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T626","span":{"begin":1028,"end":1034},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T627","span":{"begin":1268,"end":1271},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T18965","span":{"begin":46,"end":59},"obj":"Chemical"},{"id":"T74294","span":{"begin":188,"end":201},"obj":"Chemical"},{"id":"T29939","span":{"begin":270,"end":283},"obj":"Chemical"},{"id":"T23807","span":{"begin":330,"end":337},"obj":"Chemical"},{"id":"T54744","span":{"begin":355,"end":367},"obj":"Chemical"},{"id":"T56147","span":{"begin":583,"end":592},"obj":"Chemical"},{"id":"T13437","span":{"begin":659,"end":671},"obj":"Chemical"},{"id":"T2870","span":{"begin":846,"end":854},"obj":"Chemical"},{"id":"T60058","span":{"begin":936,"end":940},"obj":"Chemical"},{"id":"T24343","span":{"begin":1005,"end":1018},"obj":"Chemical"},{"id":"T39022","span":{"begin":1174,"end":1188},"obj":"Chemical"}],"attributes":[{"id":"A63721","pred":"chebi_id","subj":"T18965","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A90962","pred":"chebi_id","subj":"T74294","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A80749","pred":"chebi_id","subj":"T29939","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A99997","pred":"chebi_id","subj":"T23807","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A69781","pred":"chebi_id","subj":"T54744","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A84853","pred":"chebi_id","subj":"T56147","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A73736","pred":"chebi_id","subj":"T13437","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A55817","pred":"chebi_id","subj":"T2870","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A37412","pred":"chebi_id","subj":"T60058","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A75608","pred":"chebi_id","subj":"T24343","obj":"http://purl.obolibrary.org/obo/CHEBI_4031"},{"id":"A60789","pred":"chebi_id","subj":"T39022","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T109","span":{"begin":226,"end":241},"obj":"http://purl.obolibrary.org/obo/GO_0010467"},{"id":"T110","span":{"begin":330,"end":347},"obj":"http://purl.obolibrary.org/obo/GO_0006412"},{"id":"T111","span":{"begin":338,"end":347},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T112","span":{"begin":869,"end":897},"obj":"http://purl.obolibrary.org/obo/GO_1902679"},{"id":"T113","span":{"begin":884,"end":897},"obj":"http://purl.obolibrary.org/obo/GO_0032774"},{"id":"T114","span":{"begin":888,"end":897},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T66","span":{"begin":155,"end":164},"obj":"Phenotype"},{"id":"T67","span":{"begin":481,"end":489},"obj":"Phenotype"},{"id":"T68","span":{"begin":740,"end":752},"obj":"Phenotype"},{"id":"T69","span":{"begin":958,"end":975},"obj":"Phenotype"},{"id":"T70","span":{"begin":1221,"end":1241},"obj":"Phenotype"}],"attributes":[{"id":"A66","pred":"hp_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/HP_0012115"},{"id":"A67","pred":"hp_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A68","pred":"hp_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/HP_0032249"},{"id":"A69","pred":"hp_id","subj":"T69","obj":"http://www.orpha.net/ORDO/Orphanet_178320"},{"id":"A70","pred":"hp_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/HP_0001096"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T452","span":{"begin":0,"end":187},"obj":"Sentence"},{"id":"T453","span":{"begin":188,"end":269},"obj":"Sentence"},{"id":"T454","span":{"begin":270,"end":354},"obj":"Sentence"},{"id":"T455","span":{"begin":355,"end":526},"obj":"Sentence"},{"id":"T456","span":{"begin":527,"end":601},"obj":"Sentence"},{"id":"T457","span":{"begin":602,"end":658},"obj":"Sentence"},{"id":"T458","span":{"begin":659,"end":904},"obj":"Sentence"},{"id":"T459","span":{"begin":905,"end":982},"obj":"Sentence"},{"id":"T460","span":{"begin":983,"end":1264},"obj":"Sentence"},{"id":"T461","span":{"begin":1265,"end":1324},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1861","span":{"begin":111,"end":119},"obj":"Species"},{"id":"1862","span":{"begin":121,"end":143},"obj":"Species"},{"id":"1863","span":{"begin":149,"end":170},"obj":"Species"},{"id":"1864","span":{"begin":313,"end":321},"obj":"Species"},{"id":"1865","span":{"begin":411,"end":419},"obj":"Species"},{"id":"1866","span":{"begin":421,"end":462},"obj":"Species"},{"id":"1867","span":{"begin":464,"end":495},"obj":"Species"},{"id":"1868","span":{"begin":501,"end":519},"obj":"Species"},{"id":"1869","span":{"begin":706,"end":716},"obj":"Species"},{"id":"1870","span":{"begin":718,"end":733},"obj":"Species"},{"id":"1871","span":{"begin":735,"end":758},"obj":"Species"},{"id":"1872","span":{"begin":764,"end":781},"obj":"Species"},{"id":"1873","span":{"begin":1038,"end":1046},"obj":"Species"},{"id":"1874","span":{"begin":1115,"end":1123},"obj":"Species"},{"id":"1875","span":{"begin":1201,"end":1209},"obj":"Species"},{"id":"1876","span":{"begin":1309,"end":1317},"obj":"Species"},{"id":"1877","span":{"begin":634,"end":637},"obj":"Species"},{"id":"1878","span":{"begin":46,"end":59},"obj":"Chemical"},{"id":"1879","span":{"begin":270,"end":283},"obj":"Chemical"},{"id":"1880","span":{"begin":355,"end":369},"obj":"Chemical"},{"id":"1881","span":{"begin":536,"end":550},"obj":"Chemical"},{"id":"1882","span":{"begin":659,"end":671},"obj":"Chemical"},{"id":"1883","span":{"begin":1005,"end":1018},"obj":"Chemical"},{"id":"1884","span":{"begin":964,"end":975},"obj":"Disease"},{"id":"1885","span":{"begin":1061,"end":1069},"obj":"Disease"},{"id":"1886","span":{"begin":1106,"end":1114},"obj":"Disease"},{"id":"1887","span":{"begin":1192,"end":1200},"obj":"Disease"},{"id":"1888","span":{"begin":1215,"end":1241},"obj":"Disease"},{"id":"1889","span":{"begin":1300,"end":1308},"obj":"Disease"}],"attributes":[{"id":"A1861","pred":"tao:has_database_id","subj":"1861","obj":"Tax:694009"},{"id":"A1862","pred":"tao:has_database_id","subj":"1862","obj":"Tax:11137"},{"id":"A1863","pred":"tao:has_database_id","subj":"1863","obj":"Tax:11138"},{"id":"A1864","pred":"tao:has_database_id","subj":"1864","obj":"Tax:694009"},{"id":"A1865","pred":"tao:has_database_id","subj":"1865","obj":"Tax:1335626"},{"id":"A1866","pred":"tao:has_database_id","subj":"1866","obj":"Tax:11149"},{"id":"A1867","pred":"tao:has_database_id","subj":"1867","obj":"Tax:28295"},{"id":"A1868","pred":"tao:has_database_id","subj":"1868","obj":"Tax:12663"},{"id":"A1869","pred":"tao:has_database_id","subj":"1869","obj":"Tax:64320"},{"id":"A1870","pred":"tao:has_database_id","subj":"1870","obj":"Tax:11082"},{"id":"A1871","pred":"tao:has_database_id","subj":"1871","obj":"Tax:11588"},{"id":"A1872","pred":"tao:has_database_id","subj":"1872","obj":"Tax:11320"},{"id":"A1873","pred":"tao:has_database_id","subj":"1873","obj":"Tax:9606"},{"id":"A1874","pred":"tao:has_database_id","subj":"1874","obj":"Tax:9606"},{"id":"A1875","pred":"tao:has_database_id","subj":"1875","obj":"Tax:9606"},{"id":"A1876","pred":"tao:has_database_id","subj":"1876","obj":"Tax:9606"},{"id":"A1877","pred":"tao:has_database_id","subj":"1877","obj":"Tax:10407"},{"id":"A1878","pred":"tao:has_database_id","subj":"1878","obj":"MESH:D016572"},{"id":"A1879","pred":"tao:has_database_id","subj":"1879","obj":"MESH:D016572"},{"id":"A1880","pred":"tao:has_database_id","subj":"1880","obj":"MESH:D016572"},{"id":"A1881","pred":"tao:has_database_id","subj":"1881","obj":"MESH:D016572"},{"id":"A1882","pred":"tao:has_database_id","subj":"1882","obj":"MESH:D016572"},{"id":"A1883","pred":"tao:has_database_id","subj":"1883","obj":"MESH:D016572"},{"id":"A1884","pred":"tao:has_database_id","subj":"1884","obj":"MESH:D055370"},{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"MESH:C000657245"},{"id":"A1886","pred":"tao:has_database_id","subj":"1886","obj":"MESH:C000657245"},{"id":"A1887","pred":"tao:has_database_id","subj":"1887","obj":"MESH:C000657245"},{"id":"A1888","pred":"tao:has_database_id","subj":"1888","obj":"MESH:D007637"},{"id":"A1889","pred":"tao:has_database_id","subj":"1889","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Importantly, low micromolar concentrations of cyclosporin A (\u003c35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. Cyclosporin A significantly inhibited gene expression and reduced progeny titers. Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. It inhibited the replication of HBV, HCV, and HIV [197]. Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. By targeting cyclophilins, the drug can also prevent acute lung injury [199]. Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). It has also been used in psoriatic COVID-19 patients [200]."}